center-orphan-drug-research rare-disease-day rare-disease-day-2022 
PharmaShots
JANUARY 31, 2023
Shots: Immutable capital demands and high-spending drug development plans are the most common drivers in encouraging fully-fledged private healthcare companies to go public. Around mid-2022, the company anticipated a $6.75M IPO with a price of shares set at $5. Founded Year: 2007 No. of Shares: 1.5M of Shares: 1.2M Funding Value: $7.7M
Pharmaceutical Technology
JANUARY 27, 2023
On January 18, Sanofi launched a new warranty program for its rare blood disorder drug Cablivi (caplacizumab), which tackles value-based agreements in a slightly different way. Cablivi stops platelets from clumping together, which prevents small clots, and can be used along with other drugs that suppress the immune system.
Expert insights. Personalized for you.
40 
Let's personalize your content